Previous 10 | Next 10 |
NEW HAVEN, Conn., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , welcomes Toni-Ann Mills as the Company’s Senior Director for Learning & Development. With a ~$0.5B market potential for HemeScreen, Precipio is...
NEW HAVEN, Conn., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , will be hosting its Q2-2022 shareholder update call on Monday, August 15 th at 5:00 PM ET. The call will include updates on the Company’s curre...
Applied DNA Sciences ( APDN ) +116% . Poseida Therapeutics ( PSTX ) +81% . Ping Identity Holding ( PING ) +60% Non-GAAP EPS of -$0.34 misses by $0.22, revenue of $72.03M misses by $1.27M. Alnylam Pharmaceuticals ( ALNY ) +47% as Phase 3 tr...
Precipio ( NASDAQ: PRPO ) has entered into an agreement with Fisher Healthcare , a part of Thermo Fisher Scientific to distribute its proprietary HemeScreen assays to its customers. The Fisher Healthcare channel will enable Precipio to expand access to laboratories ac...
NEW HAVEN, Conn., July 20, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , today announced that it has entered into an agreement with Fisher Healthcare , a part of Thermo Fisher Scientific to distribute its proprietary He...
NEW HAVEN, Conn., June 14, 2022 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. ( NASDAQ:PRPO ), announced today that the Company’s 2022 Annual Meeting of Stockholders was adjourned due to the fact that the percentage of stockholders participating in ...
NEW HAVEN, Conn., June 13, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company, Precipio, Inc. (NASDAQ: PRPO) , today announced that Keith Meadors has joined Precipio as its Senior Vice President of its Products Division, to manage and drive company growth and mark...
NEW HAVEN, Conn., May 24, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company, Precipio, Inc. (NASDAQ: PRPO) , today announced that it has received CE-IVD approval for sale of its HemeScreen® reagents in the European Union. The approval was provided by the ...
NEW HAVEN, Conn., May 10, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , announced today that American Oncology Network (AON) of Fort Myers, Florida, has completed its validation of Precipio’s proprietary IV-Cell ...
NEW HAVEN, Conn., April 26, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , is excited to announce its participation and the presentation of HemeScreen, its novel diagnostic technology platform, at the Executive War College ...
News, Short Squeeze, Breakout and More Instantly...
NEW HAVEN, Conn., July 25, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , announces that its unaudited non-GAAP Cash Burn/Generated from Operations (CBFO) for Q2-2024 was $0.3M of cash generated for the quarter. It is important to not...
NEW HAVEN, Conn., July 17, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , announces that for Q2-2024, its unaudited revenues have grown from $3.4M in Q1-2024 to $4.4M in Q2-2024, an increase of 30% from one quarter ago. Patholog...
NEW HAVEN, Conn., June 13, 2024 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO) , today announced that the company’s 2024 Annual Meeting of Shareholders (“Annual Meeting”) was convened and adjourned, without any business being conducted...